Vaccination

We’re only using a fraction of health workers’ skills. This needs to change

Retrieved on: 
Tuesday, April 23, 2024

That is, before the shift of education of nurses and other health professionals into universities in the 1980s.

Key Points: 
  • That is, before the shift of education of nurses and other health professionals into universities in the 1980s.
  • But the recently released paper from an independent Commonwealth review on health workers’ “scope of practice” identifies the myriad of barriers preventing Australians from fully benefiting from health professionals’ skills.
  • But we now have a sensible pathway to improve access to care, using all health professionals appropriately.

A new vision for general practice

  • To do this, I logged onto my general practice’s website, answered the question about what I wanted, booked an appointment with the practice nurse that afternoon, got jabbed, was bulk-billed, sat down for a while, and then went home.
  • The Commonwealth government has allowed the practice to be paid by Medicare for the nurse’s work.
  • The venture capitalist practice owner has done the sums and decided allocating a room to a practice nurse is economically rational.
  • It would be good if my general practice also had a physiotherapist, who I could see if I had back pain without seeing the GP, but there is no Medicare rebate for this.

How about pharmacists?

  • Pharmacy owners especially have argued that pharmacists should be able to practise independently of GPs, prescribing a limited range of medications and dispensing them.
  • This will inevitably reduce continuity of care and potentially create risks if the GP is not aware of what other medications a patient is using.
  • Paying pharmacists independent prescribing may be part of the next agreement, the details of which are currently being negotiated.
  • So their organisations highlight the risks of these changes, reopening centuries old turf wars dressed up as concerns about safety and risk.

Who pays for all this?

  • Clearly the government must increase its support for comprehensive general practice.
  • This should be the principal direction of primary care reform, and the final report of the scope of practice review should make that clear.
  • In parallel, governments – state and federal – must ensure all health professionals are used to their best of their abilities.
  • Read more:
    Pharmacists should be able to work with GPs to prescribe medicines for long-term conditions


Stephen Duckett was a member of the Strengthening Medicare Taskforce and is a member of the Commonwealth Department of Health's Expert Advisory Panel for the Review of General Practice Incentives

How to get vaccines to remote areas? In Sierra Leone they’re delivered by foot, boat or motorbike

Retrieved on: 
Thursday, April 18, 2024

In Sierra Leone almost 59% of the population live in remote, rural areas.

Key Points: 
  • In Sierra Leone almost 59% of the population live in remote, rural areas.
  • Roads may be non-existent or in bad condition, making it very difficult for rural dwellers to access healthcare.

Why are vaccination rates low in Sierra Leone?

  • In stark contrast, only 15% of people had been vaccinated in low-income countries.
  • The hardships Sierra Leoneans face are typical of the obstacles people in low-income countries have to overcome to access healthcare.
  • In the early days of the COVID-19 vaccination campaign in Sierra Leone, it took the average Sierra Leonean living in a rural community three-and-a-half hours each way to the nearest vaccination centre.

How did this vaccine drive tackle the problem?

  • The primary aim of this intervention was to take vaccine doses and nurses to administer vaccines to remote, rural communities, preceded by seeking permission and community mobilisation.
  • At the time, only 6% to 9% of the adults who took part in the programme were already immunised.
  • The leaders were asked for their cooperation in encouraging eligible community members to take the COVID-19 vaccine.
  • Finally, vaccine doses and healthcare workers arrived at the villages to administer the doses.

Looking forward

  • This approach proved 76% more cost-effective than other vaccination campaigns.
  • Transport accounted for a large share of the costs, so the cost-effectiveness of last mile delivery can be increased by offering a “bundle” of health products.
  • Other estimates put the death toll for the same period at 14.83 million, which is 2.74 times higher.
  • Developing cost-effective strategies to make vaccines easily accessible to everyone, everywhere, is the most promising solution to prevent future pandemics.


Niccolò Francesco Meriggi receives funding from Weiss Asset Management, UKRI and the International Growth Centre.

Thailand’s Anti-Corruption Commission initiates an Anti-Corruption Education curriculum to educate Thai children and instill integrity value in society

Retrieved on: 
Wednesday, April 10, 2024

Corruption in Thai society during the past period has had enormous negative effects on the country and is a major obstacle to the country's development in all dimensions.

Key Points: 
  • Corruption in Thai society during the past period has had enormous negative effects on the country and is a major obstacle to the country's development in all dimensions.
  • However, nowadays it has changed to become more complex which is involved with a conflict of interest and policy corruption.
  • "Children and youth are the future and hope of the country we can instill the idea that corruption is an unusual thing in society.
  • All of those are considered challenging goals of the NACC in driving the anti-corruption education curriculum toward future achievement.

EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE

Retrieved on: 
Wednesday, April 10, 2024

When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.

Key Points: 
  • When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.
  • Compared to current anti-cancer strategies, vaccination can stimulate specific immune responses capable of potentially curing established tumors.
  • In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses.
  • Although the ARMTM vaccine can effectively present antigens to responding T cells, the large amount of antigen preparation required to generate the cellular vaccine might represent challenges in the clinic.

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Retrieved on: 
Tuesday, April 9, 2024

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
  • “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • Where high levels of IDO1 and PD-L1 expression were seen in the tumor microenvironment (TME), the IDO1 vaccine predominantly reduced myeloid-derived immune suppression, while the PD-L1 vaccine enhanced anti-tumor T-effector functions.
  • The poster can be found on the “ Posters & Publications ” page of the IO Biotech website and on the AACR website.

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
Friday, April 5, 2024

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Retrieved on: 
Thursday, April 4, 2024

Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.

Key Points: 
  • Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.
  • With product now available, today we are providing initial PEMGARDA net product revenue guidance in the range of $150 million to $200 million for the full year 2024.
  • For additional information about PEMGARDA, please see the full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

Retrieved on: 
Tuesday, April 2, 2024

Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.

Key Points: 
  • Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.
  • According to estimates from the CDC, two (2) million U.S. individuals are eligible for vaccination against mpox4.
  • Recent data shows 60% of this population remains completely unvaccinated, and 15% have received only one dose of the vaccine5.
  • Through its existing nationwide vaccine distribution structure, Bavarian Nordic is now making the mpox vaccine commercially available across the nation.

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024

This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.

Key Points: 
  • This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.
  • ProMIS dosed the first participants in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for AD in November 2023 (Study NCT06105528 ).
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Cash and cash equivalents were $12.6 million as of December 31, 2023, compared to $5.9 million as of December 31, 2022.